An abstract entitled "Sn-117m for metastatic bone cancer treatment-modernizing Sn-117m-DTPA for regulatory approval" was accepted for oral presentation by Serene CEO, Gilbert Gonzales, in Saskatoon, Saskatchewan July 23-27, 2023. Three additional abstracts will be presented by Serene COO, Nigel Stevenson.…
An abstract entitled "Isotopes bound to an innate immune response molecule" has been accepted for poster presentation at the 2023 SNMMI Annual Meeting in Chicago, IL, June 24-27, 2023.
Positive results of the canine elbow osteoarthritis study using Sn-117m based Synovetin OA are published in Veterinary Radiology Ultrasound. Clinical effectiveness and safety of intraarticular administration of a 117mTin radiocolloid (Synovetin OA) for treatment of early and intermediate grade osteoarthritis…
Development of an improved high specific activity tin-117m-DTPA product was initiated at Isotherapeutics Group, an experienced radiopharmaceutical development company contracted by Serene for this and numerous previous projects. FDA IND approval is expected in 2Q23, with subsequent continuation of Phase…
The Department of Energy has entered into an agreement with Serene to produce high specific activity (HSA) Sn-117m to be used in additional pre-clinical development through 2Q 2023. Thereafter, the HSA Sn-117m will be used throughout the completion of the…
A poster entitled “Localizing a Theranostic Isotope to Neuroinflammation” utilizing tin-117m linked to a new inflammation targeting molecule, has been accepted for presentation at the Alzheimer Society International Congress, now rescheduled to November 1-4, 2022 in San Francisco.
The initial patient was successfully injected with Sn-117m-DTPA in an NIH-sponsored Phase 2 clinical trial of prostate cancer patients with bone metastases at the University of Kentucky.
The Food and Drug Administration has approved a Serene, LLC IND for the use of Sn-117m DTPA for prostate cancer patients with painful bone metastases. The trial is supported by the National Cancer Institute, and will be conducted at the…
An abstract entitled "Design and bio-distribution of an apoptosis-inducing RAGE binding molecule”, was submitted to the Alzheimer’s Association Interational Conference, July 26-30, 2021, in Amsterdam.
An abstract entitled "Localizing a theranostic isotope to neuroinflammation" was accepted for platform presentation at the 2021 Alzheimer Society International Congress April 5-8 in San Francisco, CA.